You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
|
|---|---|
| Published in |
Breast Cancer Research, April 2010
|
| DOI | 10.1186/bcr2565 |
| Pubmed ID | |
| Authors |
Christos Markopoulos, Evagelos Tzoracoleftherakis, Athanassios Polychronis, Basileios Venizelos, Urania Dafni, Grigorios Xepapadakis, John Papadiamantis, Vasilios Zobolas, John Misitzis, Kyriakos Kalogerakos, Angeliki Sarantopoulou, Nikolaos Siasos, Dimitrios Koukouras, Zoh Antonopoulou, Spyros Lazarou, Helen Gogas |
| Abstract |
The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Iran, Islamic Republic of | 1 | <1% |
| Mexico | 1 | <1% |
| France | 1 | <1% |
| Unknown | 114 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 25 | 21% |
| Student > Bachelor | 12 | 10% |
| Researcher | 11 | 9% |
| Other | 7 | 6% |
| Student > Ph. D. Student | 7 | 6% |
| Other | 27 | 23% |
| Unknown | 28 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 34% |
| Agricultural and Biological Sciences | 9 | 8% |
| Nursing and Health Professions | 9 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Mathematics | 3 | 3% |
| Other | 16 | 14% |
| Unknown | 34 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2014.
All research outputs
#15,518,326
of 25,374,917 outputs
Outputs from Breast Cancer Research
#1,370
of 2,053 outputs
Outputs of similar age
#74,233
of 92,248 outputs
Outputs of similar age from Breast Cancer Research
#10
of 12 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 92,248 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.